References
- Sanchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum in full term infants. Pediatr Infect Dis J 1987; 6: 825–828
- Sanchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum from mothers to preterm infants. Pediatr Infect Dis J 1990; 9: 398–401
- Syrogiannopoulos GA, Kaptais-Zoumbos K, Decavalas GO. Ureaplasma urealyticum colonization of full term infants: Perinatal acquisition and persistence during early infancy. Pediatr Infect Dis J 1990; 9: 236–240
- Germain M, Krohn MA, Hillier SL, Eschenbach DA. Genital flora in pregnancy and its association with intrauterine growth retardation. J Clin Microbiol 1994; 32: 2162–2168
- Eschenbach DA, Nugent RP, Rao AV. A randomized placebo controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery. Am J Obstet Gynecol 1991; 164: 734–742
- Gauthier D, Meyer W, Bieniaz A. Expectant management of premature rupture of membranes with amniotic fluid cultures positive for Ureaplasma urealyticum alone. Am J Obstet Gynecol 1994; 170: 587–590
- McGregor JA, French J I, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin. Am J Obstet Gynecol 1991; 165: 632–640
- Rumpianesi F, Morandotti G, Sperning R, Satta G, Cevenini R. In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin, azithromycin and minocyclin. J Chemother 1993; 5: 155–158
- Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25: 73–82
- Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25: 109–114
- Gibbs RS, Romero R, Hillier SL, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992; 166: 1515–1528
- Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277–282
- Rylander M, Hallander HO. In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Scand J Infect Dis 1988; 53: 12–17
- Felmingham D, Robbins MJ, Sanghrajka M, Leakey A, Ridgway GL. The in vitto activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus Spp., Legionella Spp., Mycoplasma Spp. and Ureaplasma urealyticum. Drugs Exptl Clin Res 1991; 18: 91–99
- Renaudin H, Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9: 838–841
- Retsema J A, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 834–842
- Barry AL, Jones RN, Thornsberry C. Invitro activities of azithromycin (CP-62,933), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin. Antimicrobial Agents and Chemotherapy 1988; 32: 752–754